Mergers and Acquisitions
-
After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout
Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.
-
How the FTC Is Tackling ‘Below the Radar’ Healthcare Deals
The Federal Trade Commission only gets notified when a merger/acquisition deal value is above $100-$110 million, so smaller deals nonetheless lead to a slow consolidation of the market. In conference remarks, FTC Chair Lina Khan outlined the ways in which the agency is trying to counter this phenomenon.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Nestlé Sells Peanut Allergy Drug, Ending the Food Giant’s Foray Into Biotech
Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer. Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic.
-
3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff
Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity. M&A lawyer Matt Gardella said there are three sets of market circumstances that will lead to an influx of biopharma deals: a looming patent cliff, shrinking valuations and a weak IPO market.
-
Healthcare M&A Activity Reaches 3-Year Low, But It Might Pick Up in the Back Half of ‘23
M&A activity in the healthcare sector continued to decline in the second quarter of 2023, with the number of deals reaching its lowest point in three years. However, a new report predicted that M&A activity could increase in the second half of this year due to healthcare companies’ continually shrinking valuations and their divestitures of non-core assets.
-
Hospital M&A Activity Caught Up to Pre-Pandemic Levels in Q2
M&A activity among hospitals and health systems increased in Q2 of 2023 — there were 20 deals in Q2 compared to 15 deals in Q1, according to a new report. This surge brought Q2’s M&A activity levels in line with those observed before the pandemic. Q2’s 20 deal marks the highest number of announced transactions for hospitals and health systems since Q1 of 2020.
-
Thermo Fisher Adds Real-World Evidence to Remit Via $912M CorEvitas Acquisition
CorEvitas brings Thermo Fisher Scientific registries that gather data about how approved therapies are working in the real world. The acquisition will complement PPD, the contract research organization that Thermo Fisher purchased in 2021.
-
Why UnitedHealth Group Is Going All in on Amedisys
UnitedHealth Group’s Optum is acquiring Amedisys through an all-cash transaction for $101 per share, the companies announced Monday. The move represents a continuing shift to home-based care, several experts said.
-
PwC: Healthcare Deals Remained Strong in 2023 Despite Headwinds
In the 12 months leading up to May 15, health services deal volumes decreased just 4% from the year prior, a new report from PwC found. There was a 15% decrease in deal values.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Eli Lilly Bets $2.4B on Dice Therapeutics’ Oral Drugs for Psoriasis and More
Eli Lilly’s acquisition of Dice Therapeutics comes eight months after the biotech reported positive data from a Phase 1 study in psoriasis. Dice develops oral small molecule drugs intended to offer alternatives to biologic drugs that are injected or infused.
-
How California’s New Legislation Could Affect Healthcare M&A Activity
Healthcare dealmakers must prepare for a new law and a recently-introduced bill in the California Senate, both of which aim to increase oversight in the healthcare M&A space. This is a legislative trend other states are beginning to participate in too — such as New York, Massachusetts and Connecticut.
-
Novartis Lines Up $3.2B Deal for Kidney Disease Drugs, But FTC Questions Loom
Novartis is acquiring Chinook Therapeutics in a $3.2 billion deal that brings two late-stage drug candidates for a rare kidney disorder. The Novartis drug pipeline already has a molecule in late-stage development for the same kidney disease, which could raise questions from antitrust regulators.
-
FTC Files Suit to Block Amgen’s $28B Buyout of Horizon Therapeutics
The Federal Trade Commission is suing to stop Amgen’s acquisition of Horizon Therapeutics. But rather than claiming product overlap, the agency contends Amgen will use its influence to keep at bay competition for Horizon’s products.
-
Kaiser Permanente to Acquire Geisinger, Along with 5-6 More Health Systems in the Near Future
Kaiser Permanente announced that it expects to acquire Pennsylvania-based Geisinger Health. Kaiser’s move is part of a larger plan — Geisinger will be the first health system to join Risant Health, a new company Kaiser launched to operate nonprofit health systems under value-based care models. Kaiser said it expects to invest $5 billion in Risant and fold five or six health systems into the company over the next five years.
-
Adaptimmune, TCR2 Therapeutics to Combine in Marriage of Cell Therapy Developers
Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
